title: [Expression of the p185neu oncoprotein indicates an unfavorable prognosis in small, node negative breast cancer without systemic adjuvant treatment (T1N0)].
abstract: In a retrospective study, paraffin-embedded tissues from 110 primary T1 breast carcinomas (tumour diameter < or = 2 cm) were examined for the presence of the Her-2/neu encoded oncoprotein p185neu, using an immunohistochemical technique. Primary surgical therapy revealed no node involvement in 76 cases. These patients did not receive an adjuvant systemic therapy. 25% of tumours were positive for p185neu. Expression of the oncoprotein was inversely correlated to oestrogen receptor status (p < 0.05). In patients with lymph node metastases and poorly differentiated tumours, the incidence of p185neu was higher than in node negative and/or well differentiated carcinomas. However, this finding was statistically not significant. No correlations were found between the detection of the oncoprotein and age, menopausal and progesterone receptor status. The median follow-up is 85 months. In patients without lymph node metastases (n = 76), presence of the oncoprotein was significantly correlated to a shorter relapse-free and/or overall survival (p < 0.05). No such correlation was found for 34 patients with lymph node involvement. Expression of p185neu seems to mark a group of T1N0 breast cancer patients, which is at high risk and might benefit from an adjuvant therapy.
authors.affiliation: Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universität zu Köln.
authors.forename: U J
authors.initials: UJ
authors.lastname: Göhring
authors.forename: Y
authors.initials: Y
authors.lastname: Aslan-Schadwinkel
authors.forename: A
authors.initials: A
authors.lastname: Scharl
mesh_terms: D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000235:genetics* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D066246:ErbB Receptors / Q000235:genetics*; D005260:Female; D005500:Follow-Up Studies; D015972:Gene Expression Regulation, Neoplastic / Q000502:physiology; D006801:Humans; D015182:Lymphatic Irradiation; D008207:Lymphatic Metastasis; D015412:Mastectomy, Segmental; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen / Q000235:genetics; D011980:Receptors, Progesterone / Q000235:genetics; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D066246:ErbB Receptors; D011518:Proto-Oncogene Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone
vernacular_title: Die Expression des p185neu-Onkoproteins markiert eine ungünstige Prognose bei kleinen, nodal-negativen, nicht adjuvant systemisch behandelten Mammakarzinomen (T1N0).